Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Practice Management & Client Engagement
Cloud vet practice management acquired by IDEXX; Auckland New Zealand; 5,000+ clinics in US, Australia, NZ, and UK; covers patient check-in through invoicing and end-of-day reconciliation.
ezyVet is a cloud-based veterinary practice management and client engagement platform that provides veterinary clinics with patient records, scheduling, invoicing, billing, client communication, and analytics in a fully browser-based system, headquartered in Auckland, New Zealand and acquired by IDEXX Laboratories — the global veterinary diagnostics leader — in 2021 to extend IDEXX's software platform capabilities alongside its diagnostic products. ezyVet serves more than 5,000 veterinary clinics globally with particular strength in the United States, Australia, New Zealand, and the United Kingdom.\n\nezyVet's platform provides a comprehensive clinical workflow covering patient check-in, consultation and treatment planning, prescription management, invoicing, and end-of-day reconciliation. The two-way client communication features include automated appointment reminders via SMS and email, post-visit summaries, and a client portal where pet owners can access records and request appointments. Deep integration with IDEXX's diagnostic products — including in-clinic analyzers, reference laboratory services, and imaging systems — allows results to flow directly into patient records, providing a significant competitive advantage now that IDEXX owns the platform.\n\nAs an IDEXX-owned platform, ezyVet benefits from IDEXX's global distribution network, integration with IDEXX's full diagnostics portfolio, and the ability to bundle software with diagnostic equipment and service agreements. ezyVet competes with Provet Cloud, Vetspire, Digitail, and the legacy IDEXX Cornerstone platform in the veterinary software market. IDEXX's ownership creates both an advantage (deep diagnostics integration) and a competitive consideration for clinics that use non-IDEXX diagnostic products.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.